Global Glaucoma Drugs Market Size, Share and Trends Analysis Report, By Drug Class (Beta Blockers, Prostaglandins Analogs, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Others), By Disease Indication (Open Angle, Angle Closure, and Other), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Forecast Period (2022-2028)

The global glaucoma drugs market is anticipated to grow at a CAGR of 5.8% during the forecast period (2022-2028). The rising prevalence of glaucoma, increased initiatives to raise awareness about glaucoma, and technical breakthroughs in the field of ophthalmology are all driving the growth of the glaucoma drugs market. Glaucoma is the second leading cause of blindness in the globe. Glaucoma is believed to be the cause of blindness in 4.5 million individuals, according to the WHO. Glaucoma is the major cause of permanent blindness in India, affecting at least 12 million people and leaving approximately 1.2 million blind. In the community, more than 90% of instances of glaucoma go misdiagnosed.

Glaucoma is more common as people get older. Glaucoma treatments market growth is aided by an expanding pool of geriatric population and improved diagnostic technologies for detecting glaucoma. A surge in research into prostaglandin analogs has resulted in a shift in the use of this therapy class among glaucoma patients. In comparison to alternative treatment choices and drug items, the pharmacological class offers greater efficacy and fewer side effects. The increased incidence of glaucoma is being aided by the increasing screen time of gadgets such as computers and smartphones among the older population. The retail pharmacy segment is expected to increase the most. The retail pharmacy segment of the market is expected to develop due to an increase in the older population’s preference for outpatient treatments.

Some major players in the market include Aerie Pharmaceuticals, Bausch and Lomb Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Senju Pharmaceutical Co., Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

Recent Developments

• In May 2020 AbbVie Inc. bought Allergan plc in a strategic agreement. As a result of this acquisition, AbbVie Inc. has positioned itself as a market leader in the glaucoma business.
• In December 2019 Senju Pharmaceutical Co., Ltd. has announced the launch of AIBETA, glaucoma and hypertension combo medication, in Japan.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug Class
  • By Disease Indication
  • Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Aerie Pharmaceuticals, Bausch and Lomb Incorporated, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Senju Pharmaceutical Co., Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Glaucoma Drugs Market Report by Segment

By Drug Class

• Beta Blockers
• Prostaglandins Analogs
• Alpha Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Others (Combination Drugs and Other)

By Disease Indication

• Open Angle
• Angle Closure
• Other

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Glaucoma Drugs Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa